abs408.txt	background		oncolytic	viruses	are	genetically	engineered	or	naturally	occurringviruses	that	selectively	replicate	in	cancer	cells	without	harming	normal	cells	talimogene	laherparepvec	(imlygicÂ®)		the	first	oncolytic	viral	therapy	approvedfor	treatment	of	cancer		was	approved	for	treatment	of	locally	advanced	melanomain	october	2015	purpose		as	a	biologic	product		use	of	t		laherparepvec	in	the	clinical	settingrequires	pretreatment	planning	and	a	unique	systematic	approach	to	deliver	thetherapy		the	processes	we	describe	herein	could	be	adopted	by	other	centers	thatchoose	to	prescribe	t		laherparepvec	methods		we	studied	our	clinical	trial	experience	with	t		laherparepvec	before	weembarked	on	using	commercially	available	t		laherparepvec		we	created	a	standardoperating	procedure	(sop)	with	multidisciplinary	buy-in	and	oversight	fromleadership	in	infection	control	at	our	institution		we	reflected	on	clinicalcases	and	the	actual	procedures	of	administering	t		laherparepvec	to	create	thesop	results		the	preimplementation	planning		patient	selection		identification	oflesions	to	treat		the	actual	procedure		and	ongoing	assessment	of	patients	aredescribed		tumoral-related	factors	that	lead	to	unique	challenges	are	described	conclusions		a	process	to	ensure	safe	and	responsible	implementation	of	a	programto	administer	t		laherparepvec	for	treatment	of	melanoma	may	improve	the	qualityof	treatment	for	patients	who	suffer	from	advanced	melanoma	
